Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006–2024
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05443-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Florian Hitsch und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. Hauptthemen laut MEDLINE: Drug Approval, Marketing, Safety-Based Drug Withdrawals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Withdrawn drug applications (WDAs) are drug approval applications withdrawn by the applicant before the European Medicines Agency (EMA) has made a final decision. To better understand the main reasons for the emergence of WDAs, this study critically analyzes all WDAs in the period from 2006 to 2024. The data analysis is based on the 330 WDAs published by the EMA during the period mentioned above. Various parameters were analyzed, such as active substances, therapeutic subgroups and objections raised by the EMA. The most common therapeutic subgroups are antineoplastic agents ( N = 80), followed by immunosuppressants ( N = 23). Most drug approval applications are for initial approval ( N = 244; 73.9%), supported by a single key clinical trial. In 77.3% ( N = 255) of cases, the key clinical trials included a control arm (reference drug and/or placebo). In 69.7% ( N = 230) of cases, no initial marketing authorization recommendation was made by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The most common reason for this was concerns about clinical efficacy (33.46%; N = 348), partly due to inadequate clinical trial design. A major reason for the accumulation of WDAs in the antineoplastic agents group is presumably the high demand for supply and the resulting economic potential of this drug group. The present analysis may contribute to the identification of obstacles and the resulting potential for optimization in the EMA’s drug approval procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. seifert.roland@mh-hannover.de.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Hitsch, F., & Seifert, R. (2026). Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006–2024. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05443-1
Vancouver
Hitsch F, Seifert R. Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006–2024. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05443-1
BibTeX
@article{Hitsch2026,
author = {Hitsch, Florian and Seifert, Roland},
title = {Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006–2024},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05443-1}
}
EUVIMED